Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza. Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease. More information...
According to PR-model, amarincorp.com is ranked 740,075th in multilingual Wikipedia, in particular this website is ranked 427,967th in English Wikipedia.
The website is placed before iznedr.ru and after ies-salariat.org in the BestRef global ranking of the most important sources of Wikipedia.
